



Dr. Ann Hsu is currently the co-founder and Vice President of Clinical Development of LifeMax Healthcare International Corporation with primary focus on developing new products in the therapeutic areas of CNS, fibrosis and rare diseases.

Prior to LifeMax, Dr. Ann Hsu was the Vice President of Clinical Research of Impax Laboratories responsible for the clinical aspect of the branded product development program. She is the co-inventor of the patented sustained-release technology which extends the duration of the pharmacological activities of drugs with narrow GI absorption window. She also oversaw the development program from formulation to clinical to NDA (US) and MAA (EU) submissions of Rytary, a new extended-release levodopa/carbidopa formulation based on this technology.

Dr. Hsu received B.S. in Pharmacy from National Taiwan University, and Ph.D in Biopharmaceutics from College of Pharmacy, Univ. of Ill. After obtained her Ph.D., she worked at Abbott labs for 15 years. At Abbott, Dr. Hsu was a key contributor in the development of two anti-HIV protease inhibitor products: Norvir® (ritonavir) and Kaletra®. Kaletra is a combination product of lopinavir and low dose ritonavir, where ritonavir inhibits the metabolism of lopinavir. No resistance to Kaletra was noted during Phase II/III trials, even in subjects with viral rebounds. Dr. Hsu was awarded Volwiler Society Associate Research Fellow in 1997, and Volwiler Society Research Fellow in 2000 at Abbott.

Dr. Hsu co-authored 4 book chapters, 49 journal publications, and more than 120 abstracts. She was also an invited speaker in many occasions.